Skip to main content
SpringerLink
Log in

In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin

  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The in vitro activity of trovafloxacin alone and in combination with ceftazidime, meropenem, and amikacin was studied by determining the minimal inhibitory concentrations (MICs) for 111 gram-negative and 71 gram-positive bacteria. In addition, the synergy of these combinations against 46 strains of gram-negative and gram-positive organisms was studied by checkerboard titration and time-kill kinetics. Trovafloxacin exhibited excellent in vitro activity against all strains tested. Synergism was observed in 17% of the gram-negative strains and in 32% of the gram-positive strains. No antagonism was observed with any of the combinations tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Neu HC, Chin N: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 1994, 38: 2615–2622.

    PubMed  Google Scholar 

  2. Gooding BB, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 1993, 37: 349–353.

    PubMed  Google Scholar 

  3. Ball P: Emergent resistance to ciprofloxacin amongstPseudomonas aeruginosa andStaphylococcus aureus: clinical significance and therapeutic approaches. Journal of Antimicrobial Chemotherapy 1990, 26, Supplement F: 165–179.

    Google Scholar 

  4. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr: In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1993, 37: 366–370.

    PubMed  Google Scholar 

  5. Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 1994, 38: 2471–2476.

    PubMed  Google Scholar 

  6. Braveny I, Voeckl J, Machka K: Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns. Arzneimittel-Forschung 1980, 30: 491–495.

    PubMed  Google Scholar 

  7. Gootz TD, Brighty KE, Anderson MR, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR: In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 1994, 19: 235–243.

    PubMed  Google Scholar 

  8. Haller I: Comprehensive evaluation of ciprofloxacinaminoglycoside combinations againstEnterobacteriaceae andPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1985, 28: 663–666.

    PubMed  Google Scholar 

  9. Bamberger DM, Peterson LR, Gerding DN, Moody JA, Fasching CE: Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. Journal of Antimicrobial Chemotherapy 1986, 18: 51–63.

    Google Scholar 

  10. Haller I: Comprehensive evaluation of ciprofloxacin in combination with beta-lactam antibiotics againstEnterobacteriaceae andPseudomonas aeruginosa. Arzneimittel-Forschung 1986, 36: 226–229.

    PubMed  Google Scholar 

  11. Bustamente CI, Drusano GL, Wharton RC, Wade JC: Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin againstPseudomonas aeruginosa and other bacterial pathogens. Antimicrobial Agents and Chemotherapy 1987, 31: 632–634.

    PubMed  Google Scholar 

  12. Moody JA, Gerding DN, Peterson LR: Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. American Journal of Medicine 1987, 82: 44–54.

    Google Scholar 

  13. Rudin JE, Norden CE, Shinners EM: In vitro activity of ciprofloxacin against aerobic gram-negative bacteria. Antimicrobial Agents and Chemotherapy 1984, 26: 597–598.

    PubMed  Google Scholar 

  14. Meyer RD, Liu S: Synergy studies in vitro of the effect of ciprofloxacin and selected beta-lactam agents and aminoglycosides upon multidrug-resistantPseudomonas aeruginosa. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1037.

    Google Scholar 

  15. Glamarellou H, Petrikkos G: Ciprofloxacin interactions with imipenem and amikacin against multiresistantPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1987, 31: 959–961.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Medical Microbiology, Immunology and Hygiene, Trogerstr. 32, 81675, Munich, Germany

    D. Milatovic & C. Wallrauch

Authors
  1. D. Milatovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Wallrauch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milatovic, D., Wallrauch, C. In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Eur. J. Clin. Microbiol. Infect. Dis. 15, 688–693 (1996). https://doi.org/10.1007/BF01691162

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01691162

Keywords

Search

Navigation